目的 探讨甲状腺功能亢进症(甲亢)围手术期T3、T4水平的变化及其临床意义。方法 检测30例甲亢患者服碘及心得安作术前准备前(a)、术日晨(b)、术中(c)、术后第1天(d)及术后第5天(e)各时相点T3、T4水平。结果 全组患者均未发生甲状腺危象，T3、T4水平a＞b＞c＞d＞e，其中a、b、c高于正常值，d、e值在正常范围。结论 经术前准备，甲亢患者符合临床手术条件时，血T3、T4仍然高于正常水平； 手术未造成甲状腺激素大量释放； 术后12及36小时时段甲状腺危象高发期T3、T4水平不高。
Objective To analyze the clinical relationship between primary hyperthyroidism and thyroid carcinoma, and diagnosis and treatment for the combination of the two. Methods The clinical data of 15 patients with primary hyperthyroidism complicated with thyroid carcinoma from January 1998 to December 2008 were retrospectively analyzed. Results Fifteen cases were smoothly discharged. The morbidity was 2.56% (15/585) of primary hyperthyroidism complicated with thyroid carcinoma. There were no operative complications. Five cases showed thyroid nodules and all cases were performed thyroidectomy. Neither hyperthyroidism nor thyroid carcinoma recurred during 9 months to 10 years (average 5.5 years) follow-up.Conclusions The diagnosis of primary hyperthyroidism complicated with thyroid carcinoma is still difficult to be made preoperatively and chiefly depend on postoperative pathology. Rational surgical treatment can result in good effectiveness and better prognosis.
Objective To investigate the diagnosis and treatment of pulmonary arterial hypertension ( PAH) due to rare causes. Methods The clinical presentation, laboratory testing, diagnosis and treatment of 4 patients with PAH associated with rare causes in Beijing Anzhen Hospital from January 2001 to March 2008 were analysed retrospectively. Results Primary biliary cirrhosis, hyperthyroidism, antiphospholipid syndrome and pulmonary artery sarcoma may cause PAH, which were improved after corresponding diagnosis and management. Conclusion PAH can result from rare causes. The enhancement of its recognition will help earlier diagnosis and treatment and improve the prognosis.
【摘要】 目的 总结甲状腺功能亢症（甲亢）患者131I治疗中的护理特点及经验。 方法 2008年1-8月对收治的184例行131I治疗的甲亢患者，依据131I治疗特点采取针对性的护理措施：心理上帮助其消除紧张焦虑的情绪，饮食方面指导禁食碘物，并密切观察病情及预防甲亢危象，对服药中出现的一些不适症状及时对症处理。 结果 184例经131I治疗的甲亢患者3～6个月病情痊愈和缓解153例（83.15%），甲亢复发22例（11.96%），甲状腺功能减退症发生9例（4.89%）。 结论 有效对症的护理措施是甲亢患者积极配合治疗，早日获得康复的重要因素。【Abstract】 Objective To summarize the nursing characteristics and experience for the patients with hyperthyroidism treated by 131I. Methods A total of 184 patients with hyperthyroidism underwent 131I treatment between January and August 2008 were included. We took care of the patients according to the therapeutic features of 131I treatment: helped them calm down, advised not eating iodine-containing food, observed the disease condition and dealt with the discomfort after medicated. Results In 184 patients with hyperthyroidism treated by 131I treatment for three to six months, 153 (83.15 %) were cured, 22 (11.96 %) recurred, and 9 (4.89 %) had hypothyroidism. Conclusion Comprehensive nursing is a key point to make the patients with hyperthyroidism cooperate and recover.
ObjectiveTo compare the dosimetric differences among flattening filter free intensity modulated radiotherapy (3FIMRT), flattening filter free volumetric modulated arc therapy (3FVMAT), filter free intensity modulated radiotherapy (IMRT), and filter free volumetric modulated arc therapy (VMAT) for hyperthyroidism exophthalmus patients.MethodsComputed tomography (CT) scans of 29 patients, who were diagnosed with hyperthyroidism exophthalmus and treated with radiation therapy between September 2016 and September 2017, were selected for study. Four treatment plans with the same dose prescription and objective constrains were designed for each patient based on their images, consisting of IMRT, VMAT, 3FIMRT, and 3FVMAT. The target dosimetric distribution, normal tissue radiation dose, monitor units, and treatment time of each plan were evaluated.ResultsFour types of plans were all able to satisfy the clinical treatment requirements, and there were no significant differences in maximum dose, mean dose (Dmean), homogeneity index of the targets (P>0.05). For the parameters minimum dose, V50%, conformity index (CI), gradient index of the targets, statistically significant differences were observed among the four kinds of technologies (F=10.920, 35.860, 11.320, 17.790; P<0.05). The CI of IMRT and 3FIMRT were superior to those of VMAT and 3FVMAT, but there was no significant difference between IMRT and 3FIMRT. In terms of Lens Dmean and Brain Dmean, statistically significant differences were observed among the four kinds of technologies (F=5.054, 83.780; P<0.05). For Lens Dmean and Brain Dmean, 3FVMAT achieved better sparing effects when compared with the other three plans. The total monitor units and treatment time did not significantly differ between 3FVMAT and VMAT. The mean monitor units of 3FVMAT were 65.07% and 70.22% less than that of IMRT and 3FIMRT respectively. The mean treatment time of 3FVMAT were 48.1% and 35.24% less than that of IMRT and 3FIMRT respectively.Conclusion3FVMAT can bring more dosimetric advantages for hyperthyroidism exophthalmus radiation therapy when compared with IMRT, 3FIMRT, and VMAT.
目的 总结甲状腺功能亢进症（甲亢）并肝损害的临床特征与治疗转归。 方法 回顾性分析2009年6月－2010年6月入院诊治的119例甲亢并肝损害患者（肝损害组）的临床特点与治疗转归资料，并与同期247例甲亢不伴有肝损害患者（无肝损害组）作比较。 结果 肝损害组占同期甲亢患者的30.4%，其中108例（90.8%）无明显肝损害的临床表现，以丙氨酸氨基转移酶和天门冬酸氨基转移酶升高为主，多为轻、中度升高；患者高代谢症候群、突眼、甲状腺肿大发生率及肿大程度明显高于无肝损害组，心率明显快于无肝损害组，血清游离三碘甲状腺原氨酸、游离甲状腺素及吸131I率明显高于无肝损害组，而体质量指数则明显低于无肝损害组（P＜0.05）。两组性别、年龄、病程、甲亢类型、甲状腺球蛋白抗体及甲状腺微粒体抗体滴度差异无统计学意义（P＞0.05）。肝损害组患者随访18个月以上，101例131I治疗患者随着甲亢控制，肝功能恢复正常，未见有再发肝损害；18例抗甲状腺药物治疗，其中10例随着甲亢控制，肝功能逐渐恢复正常；8例随着甲亢控制，肝功能逐渐恢复正常，但随着甲亢复发，再出现肝功能损害。 结论 肝损害是甲亢的常见并发症之一，其肝损害症状较轻，多数患者不典型，但并随甲亢病情较重。护肝治疗结合恰当的抗甲亢治疗预后良好。